Interleukin-2 (IL-2) is a pluripotent cytokine that regulates the immune system’s response. The IL-2 receptor (IL-2R) is a heterotrimeric protein that binds to IL-2 and reacts to it on the ...
Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...
Almirall has licensed an interleukin-2 (IL-2) drug from China's Simcere Pharma, joining the ranks of companies looking at blocking the cytokine as a way to treat autoimmune diseases.
Despite setbacks for projects trying to harness the power of the cytokine interleukin-2 (IL-2) as a cancer therapy, there are still plenty of players on the field – and Roche has just joined ...
The drug, SAR444245, is part of an emerging class of cancer immunotherapies based on interleukin-2 (IL-2). This cytokine is a protein that coaxes a powerful immune response against cancer cells.
from the Utrecht Medical Centre in The Netherlands provides the first clinical evidence, to the authors' knowledge, that local interleukin-2 (IL-2) therapy in combination with radiotherapy is an ...
A new study showed that SOCS1 regulation of GM-CSF signaling is dose-dependent. The study, which involved generating a novel ...
Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced an ag ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...